Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection.
Aksyuk AA, Bansal H, Wilkins D, Stanley AM, Sproule S, Maaske J, Sanikommui S, Hartman WR, Sobieszczyk ME, Falsey AR, Kelly EJ. Aksyuk AA, et al. Among authors: stanley am. Cell Rep Med. 2023 Jan 17;4(1):100882. doi: 10.1016/j.xcrm.2022.100882. Epub 2022 Dec 15. Cell Rep Med. 2023. PMID: 36610390 Free PMC article.
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
Maaske J, Sproule S, Falsey AR, Sobieszczyk ME, Luetkemeyer AF, Paulsen GC, Riddler SA, Robb ML, Rolle CP, Sha BE, Tong T, Ahani B, Aksyuk AA, Bansal H, Egan T, Jepson B, Padilla M, Patel N, Shoemaker K, Stanley AM, Swanson PA, Wilkins D, Villafana T, Green JA, Kelly EJ. Maaske J, et al. Among authors: stanley am. Front Immunol. 2023 Jan 13;13:1062067. doi: 10.3389/fimmu.2022.1062067. eCollection 2022. Front Immunol. 2023. PMID: 36713413 Free PMC article. Clinical Trial.
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine.
Benkeser D, Fong Y, Janes HE, Kelly EJ, Hirsch I, Sproule S, Stanley AM, Maaske J, Villafana T, Houchens CR, Martins K, Jayashankar L, Castellino F, Ayala V, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Isaacs MB, Makhene M, Tong T, Robb ML, Corey L, Neuzil KM, Follmann D, Hoffman C, Falsey AR, Sobieszczyk M, Koup RA, Donis RO, Gilbert PB; AstraZeneca AZD1222 Clinical Study Group; Immune Assays Team; United States Government (USG)/CoVPN Biostatistics Team. Benkeser D, et al. Among authors: stanley am. NPJ Vaccines. 2023 Mar 11;8(1):36. doi: 10.1038/s41541-023-00630-0. NPJ Vaccines. 2023. PMID: 36899062 Free PMC article.
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
Ahani B, Tuffy KM, Aksyuk AA, Wilkins D, Abram ME, Dagan R, Domachowske JB, Guest JD, Ji H, Kushnir A, Leach A, Madhi SA, Mankad VS, Simões EAF, Sparklin B, Speer SD, Stanley AM, Tabor DE, Hamrén UW, Kelly EJ, Villafana T. Ahani B, et al. Among authors: stanley am. Nat Commun. 2023 Jul 19;14(1):4347. doi: 10.1038/s41467-023-40057-8. Nat Commun. 2023. PMID: 37468530 Free PMC article. Clinical Trial.
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
Ahani B, Tuffy KM, Aksyuk AA, Wilkins D, Abram ME, Dagan R, Domachowske JB, Guest JD, Ji H, Kushnir A, Leach A, Madhi SA, Mankad VS, Simões EAF, Sparklin B, Speer SD, Stanley AM, Tabor DE, Hamrén UW, Kelly EJ, Villafana T. Ahani B, et al. Among authors: stanley am. Nat Commun. 2024 Apr 8;15(1):3026. doi: 10.1038/s41467-024-47421-2. Nat Commun. 2024. PMID: 38589384 Free PMC article. No abstract available.
Report of the Executive Committee for 2021.
Ashcroft AT, Stanley AM. Ashcroft AT, et al. Among authors: stanley am. Acta Crystallogr A Found Adv. 2023 Jan 1;79(Pt 1):95-131. doi: 10.1107/S2053273322007598. Epub 2023 Jan 1. Acta Crystallogr A Found Adv. 2023. PMID: 36601766
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.
Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, Patwardhan M, Tyler H, Raheja R, Stanley AM, Pineda-Salgado L, Bourdet DL, Andrade RJ, Hayashi PH, Dimick-Santos L, Rockey DC, Estilo A. Hey-Hadavi J, et al. Among authors: stanley am. Drug Saf. 2021 Jun;44(6):619-634. doi: 10.1007/s40264-021-01051-5. Epub 2021 Mar 16. Drug Saf. 2021. PMID: 33725335 Free PMC article. Review.
36 results